Inja Waldhauer

Schlieren, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs.

Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs.

Journal: mAbs

Published: November 06, 2025

First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma.

First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma.

Journal: Neuro-oncology advances

Published: August 22, 2025

An alternative nonclinical approach to support the first-in-human clinical trial of a T-cell bispecific targeting EGFRvIII.

An alternative nonclinical approach to support the first-in-human clinical trial of a T-cell bispecific targeting EGFRvIII.

Journal: Journal of pharmaceutical sciences

Published: July 09, 2025

Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure.

Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure.

Journal: Frontiers in oncology

Published: November 29, 2023

Correction: Preclinical In Vivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T‑Cell Bispecific in Combination with Anti‑PD‑L1.

Correction: Preclinical In Vivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T‑Cell Bispecific in Combination with Anti‑PD‑L1.

Journal: The AAPS journal

Published: March 31, 2023

Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1.

Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1.

Journal: The AAPS journal

Published: June 23, 2022

Investigating brain uptake of a non-targeting monoclonal antibody after intravenous and intracerebroventricular administration.

Investigating brain uptake of a non-targeting monoclonal antibody after intravenous and intracerebroventricular administration.

Journal: Frontiers in pharmacology

Published: May 31, 2022

A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma.

A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma.

Journal: Molecular cancer therapeutics

Published: March 25, 2022

Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.

Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.

Journal: mAbs

Published: May 11, 2021

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells.

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells.

Journal: Nature

Published: March 14, 2021

A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.

A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.

Journal: Journal of autoimmunity

Published: July 31, 2018

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

Journal: Oncoimmunology

Published: October 26, 2016

Showing 1-12 of 18

Last Updated: 09/26/2026